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Abstract 
GOAL: To investigate the HPV prevalence and characterize the expression of potential molecular surrogate 
markers of HPV infection in esophageal squamous cell carcinoma.  
MATERIALS AND METHODS: The prevalence of HPV in individuals with and without esophageal 
cancer (EC) was determined by using multiplex PCR; p16 and p53 protein levels were assessed by 
immunohistochemistry (IHC).  
RESULTS: High-risk HPV (hr-HPV) was found in the same frequency (13.8%) in esophageal squamous cell 
carcinoma (ESCC) and in healthy individuals. The p53 expression was positive in 67.5% of tumor tissue, 20.0% 
of adjacent non-tumoral tissue and 1.8% of normal esophageal tissue. p16 was positive in 11.6% of esophageal 
cancer cases and 4.7% of adjacent non-tumoral tissue. p16 was undetectable among control group samples. 
p53 and p16 levels were not significantly associated with the HPV status.  
CONCLUSIONS: These results suggest that hr-HPV types are not associated with the development of 
ESCC and that p53 and p16 protein expression have no relationship with HPV infection in normal or 
cancerous esophagus. 
Key words: Esophageal neoplasias, p16, p53, immunohistochemistry, HPV. 
Introduction 
Esophageal cancer (EC) represents the eighth 
highest incidence of cancer worldwide (456,000 
cases/year), and is usually diagnosed at an advanced 
stage, showing rapid progression and extremely poor 
prognosis [1, 2]. For this reason, it is ranked as the 
sixth most common cause of cancer death 
(400,000/year) [1]. In Brazil, EC is among the ten most 
common incident cancers, ranking sixth among men 
and thirteenth among women, with the higher 
incidences occurring in southern and southeast Brazil 
[3], supposedly associated with the high consumption 
of mate tea [4, 5]. 
The etiology of esophageal squamous cell 
carcinoma (ESCC) is complex and the geographical, 
cultural and ethnic variations observed suggest an 
association of established risk factors for this disease, 
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such as alcohol consumption, smoking, malnutrition, 
environmental factors, and infectious pathogenic 
microorganisms [6, 7]. 
In the early 80s, Syrjänen et al. (1982) identified 
for the first time features of HPV cytopathic infection 
in benign and malignant esophageal tumors [8]. 
However, studies with populations of varied cultural 
characteristics, associated with the use of different 
viral detection methodologies resulted in significantly 
heterogeneous data concerning HPV prevalence and 
viral types identified in ESCC [9-11], something that 
encourages further research in this area and requires 
knowledge of both molecules activated by the virus, 
and the expression of surrogate infection markers 
[12]. 
During persistent high-risk HPV (hr-HPV) 
infection, the increased expression of viral 
oncoproteins E6 and E7 can interfere with cell cycle 
control and trigger chromosomal instability [13, 14] 
since they inactivate p53 and pRb tumor-suppressor 
protein (retinoblastoma protein), respectively, 
resulting in increased 16INK4A and p53 expressions. 
Hence, immunohistochemistry (IHC) for p16 and p53 
expression is considered as assay for detection of 
surrogate markers of HPV infection in genital and 
oropharyngeal carcinomas [15-18].  
In HPV positive oropharyngeal, cervical and 
vaginal tumors [15, 17, 19], the p16 expression is 
altered, and abnormal p53 expression has also been 
reported in HPV-positive oropharyngeal carcinoma 
[19] and penile lesions [20]. Furthermore, clinical 
development of these HPV-induced tumors, related to 
the treatment response and overall survival, is 
favorable when compared to HPV negative tumors 
[21, 22]. For this reason, the investigation of these 
proteins in ESCC is appropriate and may be an 
efficient research tool to find potential tumor markers 
[23, 24]. 
Therefore, this study aimed at investigating the 
prevalence of HPV in ESCC and normal esophageal 
tissue and also evaluates p16 and p53 expression 
levels in HPV positive esophageal cancers. 
Materials and Methods 
From January 2013 to October 2014, patients 
newly admitted to the Upper Digestive Department at 
Barretos Cancer Hospital referred for upper digestive 
endoscopy were screened and a total of 101 patients 
diagnosed with primary ESCC were enrolled. For the 
control group, 101 individuals aged 18 years or over, 
undergoing upper gastrointestinal endoscopy for 
reasons other than esophageal malignancy and with 
no microscopic or gross esophageal pathology 
admitted to the Ambulatory of Medical Specialties 
(AME, acronym in Portuguese) in Barretos were 
screened and matched by gender and age (+/- 3 
years) with the cases. Sample size of the prospective 
and controlled study was based on a previously 
published work [25]. All individuals participating in 
this study signed an informed consent prior to 
enrollment and completed a questionnaire regarding 
their socio-demographical and lifestyle information. 
Moreover, clinic-pathological information was 
obtained through medical record review. The protocol 
was approved by the Ethics Committee at Barretos 
Cancer Hospital. 
Exclusion criteria 
Volunteers that had been submitted to adjuvant 
and/or neoadjuvant therapy, displaying any mental 
disability or an unfavorable clinical condition that 
would render them unfit for procedures, or that could 
provide insufficient amount of sample and/or 
inadequate sample quality were excluded.  
Samples collection 
Samples used in this project were collected 
during endoscopy and processed by the Pathology 
Department for diagnosis. Of the 101 patients with EC 
initially recruited for this study, only 87 samples had 
the enough DNA quantity to be included in the 
present study. Therefore, 87 controls were matched 
and included in the analysis. During the endoscopy 
procedure, biopsies were preceded by visual 
examination, and sample collection was conducted in 
the following order: tumor tissue and adjacent 
non-tumoral tissue for cases; proximal and distal 
esophageal tissue for controls. Biopsies fixed in 10% 
buffered formalin and embedded in paraffin were 
examined by a senior pathologist (CSN). 
HPV detection and characterization 
Biopsy specimens were digested with proteinase 
K-SDS 1%; DNA was obtained by organic extraction 
[26]. HPV DNA was assessed in all samples using a 
type-specific PCR bead-based multiplex genotyping 
(TS-MPG) assay that combine multiplex polymerase 
chain reaction (PCR) and bead-based Luminex 
technology (Luminex Corp., Austin, TX, USA), as 
cited in another paper [27]. This methodology is able 
to identify 21 HPV types [28, 29]. Based on their 
frequency in cervical cancer and available biological 
data, 12 of these types, namely types 16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58 and 59 have been deﬁned as 
carcinogens (IARC Group 1A)—hereafter referred to 
as hr-HPV. For eight other types, in the high-risk 
clade, namely types 26, 53, 66, 67, 68, 70, 73 and 82, the 
combination of their low frequency, lack of data on 
their active transcription and their transforming 
potential in model systems, has led them to be 
classiﬁed as only probable/possible carcinogens 
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(IARC Groups 2A and 2B)—hereafter referred to as 
possible high-risk (pHR)-HPV types [30]. 
As a positive control for the quality of the 
template DNA, primers for β-globin gene were 
included in the reactions. PCRs were performed with 
10µL of template DNA in a 96-well format in 
25-μl/well final reaction volume. HPV multiplex PCR 
was performed with QIAGEN Multiplex PCR Kit 
(Qiagen, Dusseldorf, Germany), according to 
manufacturer’s instructions. Each reaction consisted 
of 45 cycles: 94°C for 30 seconds, 63°C for 3 minutes, 
and 72°C for 90 seconds. The first cycle was preceded 
by incubation at 95°C for 15 minutes and the last cycle 
was extended for 10 minutes at 72°C. PCR negative 
control consisted of a reaction mix without DNA. 
Hybridizations were performed according to 
Schmitt et al (2006) [31]. For each HPV type-specific 
probe, the mean fluorescence intensity (MFI) values 
obtained when no PCR product was added to the 
hybridization mixture was considered as background. 
The cutoffs were calculated by adding 5 MFI to 1.1 
times the value of the median background. MFI 
values > 20 were considered positive. 
Immunohistochemistry  
Expressions of p16 and p53 proteins were 
assessed by IHC using anti-p16 (monoclonal mouse 
anti-human p16INK4A protein, Clone E6H4TM, 
ready for use, Ventana, Tucson, AZ, USA) and 
anti-p53 (monoclonal mouse anti-human p53 protein, 
Clone DO-7, dilution 1:1200, Cell Marque, Rocklin, 
CA, USA) in an automated system (Ventana 
Benchmark ULTRA, Tucson, AZ, USA). Briefly, 
formalin-fixed, paraffin-embedded tumor specimens 
(4 μm) were deparaffinized by heating (75°C for 4 
minutes), and antigen retrieval was achieved by use 
of cell conditioning buffer 1 (CC1) at 95°C for 64 
minutes. Specific primary antibodies were separately 
added, and ultraView Universal DAB Detection Kit 
polymer amplification system (Ventana Medical 
Systems, Tucson, AZ, USA) was used according to 
manufacturer's instructions.  
A cervical adenocarcinoma was used as positive 
control for p16 staining (Figure 2 E) and negative 
controls were obtained by omitting the primary 
antibodies (Figure 2 D). Samples with strong and 
diffuse nuclear and cytoplasmic in more than 70% of 
the tissue were considered positive [32, 33]. All 
scorings were conducted blindly by two observers 
(CSN and ALF). A colon carcinoma sample with a 
diffuse nuclear p53 staining was used as a positive 
control for p53 labelling (Figure 2 B) whilst a breast 
carcinoma sample was used as a negative control 
(Figure 2 A). The slides were evaluated for nuclear 
expression, and samples with at least 10% of strong 
nuclear staining [34] were considered positive for the 
p53 expression. All scorings were conducted with no 
knowledge of clinical characteristics or outcome by 
two observers (CSN and ALF), independently. The 
scanning of histological images was performed using 
the Olympus BX43 microscope and the Olympus Soft 
Imaging Solution GmbH, version 5.2 software 
(Olympus Corporation, Shinjuku-ku, Tokyo, Japan). 
The observers revised all immunohistochemical 
discordant cases and consensus was achieved. 
Statistical Analyses 
The description of the study population was 
made from frequency tables. Chi-square, Fisher's 
exact, McNemar and Q-Cochran tests were used for 
comparison between groups (cases x controls; 
negative HPV x positive HPV). The significance level 
was 0.05 (5%). All analyses were conducted using the 
IBM® SPSS® Statistics 21.0 software for Windows 
(IBM Corporation, Somers, NY, USA). 
Results 
Figure 1 shows the number of samples included 
in the HPV analysis and p53 and p16 IHCs. Then, the 
characteristics of population with 174 volunteers (87 
cases and 87 controls) were described. Overall, the 
majority of the study population was composed by 
men (78.2%) with an average age of 60 years. 
However, when lifestyle was investigated, it was 
shown that the intake of alcohol (90.8%), tobacco 
smoking (81.6%) and alcohol intake associated with 
tobacco smoke (75.9%) was significantly higher 
among individuals in the case group compared to 
controls individuals (74.7%; 67.8%; 60.9%, 
respectively) (Table 1). 
 
Table 1. Characterization of study population 
Variable / Category Cases  Controls  p* 
n (%)  n (%)  
Gender        
Male 68 78.2  68 78.2  1.000 
Female 19 21.8  19 21.8   
Age        
≤ 60 years 46 52.9  42 48.3  0.544 
>60 years 41 47.1  45 51.7   
Alcohol        
No 8 9.2  22 25.3  0.005 
Yes 79 90.8  65 74.7   
Tobacco        
No 16 18.4  28 32.2  0.036 
Yes 71 81.6  59 67.8   
Alcohol + Tobacco        
Never drank or smoked 3 3.4  16 18.4  0.006 
Drinks and smokes 66 75.9  53 60.9   
Drinks or smokes 18 20.7  18 20.7   
*Used test: Qui-square 
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Figure 1. Clinical Samples included in the present study *As our study was case-control, only the 87 controls matched with cases were assessed in the work. ** For 
counting of subjects evaluated for p53 and p16 proteins expression by IHC was considered that individuals with at least one analysis to the tissues for the control 
group (proximal and/or distal esophageal tissues) and tumor tissue for case group. *** This analysis could not be performed for all individuals included in the study due 
to lack of material. 
 
Among the 87 analyzed esophageal tumors, 
most of them (59%) were moderately differentiated, 
localized in the middle third of the esophagus (55.2%) 
and with TNM staging as advanced (73.5%). 
Moreover, a review of medical records held in May 
2016 provided the information that 75.9% of patients 
in the study died due to the disease and only 14.9% 
were still alive without ESCC (Table 2).  
Table 2. Characterization of tumor tissue 
Variable Category  n % 
Degree of 
differentiation 
Well   11 13.3 
 Moderate  49 59.0 
 Little  23 27.7 
Topography Upper third  3 3.4 
 Middle third  48 55.2 
 Lower third  7 8.0 
 More than one location  29 33.3 
TNM Staging I and II  22 26.5 
 III and IV  61 73.5 
T T1/T2  10 13.0 
 T3/T4  67 87.0 
N N0  22 38.6 
 N positive  35 61.4 
M M0  65 79.3 
 M1  17 20.7 
Patient status Death due to cancer  66 75.9 
 Alive with disease  8 9.2 
 Alive without disease  13 14.9 
To evaluate HPV DNA prevalence in the 
esophagus, tissues were initially examined separately 
in tumor and adjacent non-tumoral tissue for cases 
and, proximal and distal esophageal tissues for 
controls. The results obtained were, respectively: 
11.5% (10/87), 2.3% (2/87), 10.3% (9/87) and 4.6% 
(4/87). The overall frequency of HPV in each group 
was considered as positive when the individual had 
DNA HPV in at least one tissue. Thus, the frequency 
of DNA HPV was 13.8% for both of groups. 
Table 3 shows the frequency of HPV types 
detected in each anatomical region analyzed. 
Regarding the adjacent non-tumoral tissue, two 
different hr-HPVs (HPV 31 and 66) were detected in 
equal proportion (1.15%). However, for tumor tissue, 
HPV 16 (2.3%), 18 (1.15%), 51 (1.15%), 31 (1.15%), 66 
(1.15%) types, in addition to coinfections (4.6%) were 
detected. In controls tissues, HPV 56 (2.3%), 16 
(1.15%), 31 (1.15%), 51 (1.15%), 26 (1.15%) types and 
coinfections (3.4%) were detected in proximal 
esophagus, whilst in the distal esophagus, only four 
coinfections (4.6%) were found. Importantly, no 
low-risk DNA HPV was detected in samples 
analyzed. 
We observed no significant association between 
the detection of HPV DNA and any of the different 
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variables analyzed (gender, age and consumption of 
alcohol and tobacco, isolated or combined). In 
addition, HPV prevalence, clinicopathological 
characteristics (histological degree and TNM staging) 
and status of the patient were not significantly related 
(p=NA*, p=0.502, p=NA*, respectively) (*could not be 
calculated). 
Table 3. Frequency of the HPV types detected by Luminex 
Variable Cases Controls 
Adjacent 
normal 
Tumor Proximal Distal 
n (%) n (%) n (%) n (%) 
HPV 51 0 0.0 1 1.15 1 1.15 0 0.0 
HPV 31 1 1.15 1 1.15 1 1.15 0 0.0 
HPV 66 1 1.15 1 1.15 0 0.0 0 0.0 
HPV 56 0 0.0 0 0.0 2 2.3 0 0.0 
HPV 18 0 0.0 1 1.15 0 0.0 0 0.0 
HPV 16 0 0.0 2 2.3 1 1.15 0 0.0 
HPV 26 0 0.0 0 0.0 1 1.15 0 0.0 
Coinfecction 0 0.0 4* 4.6 3** 3.4 4*** 4.6 
Total 2 2.3 10 11.5 9 10.3 4 4.6 
Frequencies refer to HPV types detected in each tissue analyzed by Luminex. 
*56,66; 39,53,66; 53,66; 16,53. 
**16,66; 18,31,33,53; 45,53. 
***16,31; 31,59; 16,39,51; 31,45,53. 
 
p53 and p16 immunohistochemistry 
Regarding cellular proteins expression, we 
observed that p16 and p53 levels were significantly 
higher in tumor tissues (67.5% for p53 and 11.6% for 
p16) than in control group (1.8% for p53 and 0% for 
p16) (p <0.001) (Figure 2). p53 expression was 
considered positive in 67.5% of tumor tissues (Figure 
2C), 20.0% of adjacent non-tumoral tissue and 1.8% of 
normal esophageal tissue. Furthermore, p16 
expression was observed in 11.6% of tumor tissues 
(Figure 2F) and 4.7% of adjacent non-tumoral tissue 
specimens. No p16 expression was observed in the 
control group. p53 and p16 expression levels were not 
significantly associated with HPV status. 
Table 4 shows the number of samples that 
showed agreement and disagreement regarding the 
p16 expression and the presence of HPV. The majority 
of samples (80.9%) were double negative concordant 
(p16-/HPV-). Only one case (0.6%) showed 
concomitant concordance for positive p16 expression 
and the presence of HPV. Interestingly, this case did 
not show characteristics that distinguishes those 
negative for p16 since was a man aged 73, non-white, 
with ESCC moderately differentiated type, advanced 
stage (III), negative expression for p53, was alcohol 
intake associated with tobacco smoke and died due to 
cancer. Furthermore, 32 samples were discordant to 
p16 IHC and HPV results, wherein 9 p16 positive 
samples (5.2%) were HPV negative whilst 23 (13.3%) 
samples were negative for p16 expression, but 
positive for HPV. 
Table 4. Agreement between p16 expression and HPV DNA in 
esophageal samples 
Agreement Samples 
n (%) 
   
p16- HPV - 140 80.9 
   
p16+ HPV + 1 0.6 
   
p16+ HPV - 9 5.2 
   
p16- HPV + 23 13.3 
Frequency samples with concordant results between the HPV status and the 
expression of p16 protein for subjects in the study. 
 
Discussion 
The role of HPV in esophageal carcinogenesis is 
a controversial issue that has been described with 
significant discrepancies in results, which may be 
attributed to the different methodologies employed in 
the HPV DNA detection and, in the many ways, in 
which sample may be collected and preserved [35] 
and, maybe, the most important, the characteristics of 
individuals enrolled, including their sexual practices 
and social-demographic data [36]. Thus, to our 
knowledge, this is the first study having a prospective 
design and controlled in Brazil, which provides 
important reliability to the results. The goal of this 
project was to obtain Brazilian data that would help 
clarify the frequency of HPV in ESCC and the 
molecular pathways involved in this esophageal 
cancer development process, besides gathering 
evidences that could assist in the prognostic 
evaluation of patients affected by such a malignancy 
or the prevention of the disease through an HPV 
vaccine. 
We demonstrated that HPV frequencies were 
identical in case and control groups (13.8%) by using 
Luminex® technology. The HPV frequency in 
esophageal tumors we detected is consistent with 
other studies conducted in Brazil in which the HPV16 
and 18 prevalence found was 15.75% by using Nested 
PCR methodology [37] and 13.0% by using PCR 
followed by sequencing and in situ hybridization 
(HPV16 was the most frequent type) [38]. However, 
this prevalence is higher than others that described 
HPV prevalence in Brazilian cases of esophageal 
cancers around 2.5% of low-risk HPV using hybrid 
capture methodology [39] and 0.0% using nested PCR 
methodology [40]. Furthermore, in non-cancer 
volunteers, the HPV frequency of 13.8% was similar to 
the first Brazilian study carried out with samples from 
South of the country which found an HPV prevalence 
of 10% in normal esophageal samples by hybrid 
capture methodology [39]. However, all other 
Brazilian studies did not detect DNA HPV in healthy 
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esophageal samples analyzed [37, 38, 40], and this 
confirms unequivocally that the frequency of HPV in 
neoplastic and normal esophageal tissues are so 
variable, not only for any regional differences, but 
also very important, according to the methodological 
techniques used to address this goal [35, 36]. 
Differences in HPV prevalence largely depend 
on the test used and type of the samples and their 
conservation. The variation among the groups did not 
come as a surprise but the real meaning of the 
findings did. This point was elegantly reported in a 
recent review of the literature [35]; worldwide 
HPV-ESCC infection rates ranged from 11.7% to 
39.9%, with the high-ESCC-incidence countries 
relating HPV tumor infections rates significantly 
higher in relation to low-ESCC-incidence countries. In 
China, in a high-ESCC-incidence region, for example, 
HPV infections in ESCC ranged from 32.8% to 63.6%, 
whereas in North America (low incidence region) 
rates ranged between 8.7% to 16.6% [35]. Li et al. 
(2014) also reported that the positive rate for HPV in 
ESCC was 14.0% for Europe and the Americas, 
according to our findings [11]. In relation to adjacent 
non-tumoral esophageal tissue, literature has shown 
rates as high as 58.9% in some studies, and as low as 
0% in others. Such disparities may be justified by the 
small sample size, making it hard to answer questions 
of the HPV ESCC prevalence [35]. 
Global data shown by recent literature indicates 
that HPV has no significant etiological role in most 
cases of ESCC [35]. Another recent study showed that 
HPV infection may play a role in esophageal 
carcinogenesis only in high-incidence regions [41] and 
this conclusion corroborates, in part, the results 
demonstrated by our study, since we found identical 
HPV frequency in patients without EC group 
compared to the group with ESCC. To confirm, no 
correlation with p16 and p53 expression with tumor 
was observed and they are canonic pathways altered 
in HPV-cervical cancer. 
 
 
Figure 2. p53 and p16 immunohistochemistry in ESCC (A) Negative control for p53 staining. (B) Positive control for p53 staining. (C) Infiltrative moderately 
differentiated ESCC tissue with p53 strong nuclear expression. (D) Negative control for p16 staining. (E) Positive control for p16 staining. (F) Infiltrative poorly 
differentiated ESCC tissue with strong expression of p16. All images were obtained with 20X magnification. 
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Despite the HPV frequency be similar, the HPV 
types detected by us is different from those reported 
by other Brazilian studies, since the HPV 16 and 18 
types were less frequent in our casuistry [39, 40]. 
However, although less frequent, the HPV types we 
detected had already been detected in ESCC in 
different geographic regions of the world [HPV 16 
(11.4%), 18 (2.9%), 52 (1.1%), 33 (0.8%) and 31 (0.6%)] 
[11]. In South America, HPV types most often found 
in the cervix are HPV 16, 58, 18, 45 and 31, whereas, 
only HPV types 16, 18 and 31 are cited as frequently in 
cervical and esophageal cancer. From this 
information, it is strongly suggested that the main 
types of HPV that infect the esophageal mucosa in the 
Brazilian population are different from those that 
infect the lining of the cervix and esophagus in other 
regions the world [42]. 
In addition to detecting HPV presence in normal 
and tumoral esophageal tissues, we also evaluated the 
p53 and p16 proteins expression, since it is known 
that the altered expression (increased or reduced) of 
these proteins is directly related to tumor progression 
in several types of cancers, induced or not by HPV. 
Although there are a significant number of positive 
HPV samples, they were not associated with p16 and 
p53 expression in this study. However, the expression 
of these proteins increases progressively with the 
severity of esophageal injury, corroborating previous 
studies [43, 44].  
According to p16 expression and HPV status in 
esophageal samples from patients with and without 
EC, we found only one sample (0.6%) with concordant 
results p16+/HPV+. This result corroborates recent 
systematic review, where it was shown that, unlike 
the results for cervical and oropharynx cancer, in EC 
there is slight or no correlation between p16 
overexpression and the HPV positivity. By bringing 
together studies in EC, the authors concluded that the 
rate of double positivity (HPV+/p16+) is below 5% of 
cases [35]. Although some studies on head and neck 
show strong relationship between p16 expression and 
the HPV presence, it was shown that tests for HPV 
DNA and p16 immunohistochemistry were not 
satisfactorily consistent, and that the use of only one 
of these tests is inadequate to confirm the viral origin 
of oropharyngeal cancer [45]. 
We observed that 9 esophageal samples (5.2%) 
were p16+/HPV-, and similar result obtained by 
Fonmarty et al. (2015), who analyzed the p16 
expression and HPV status of oropharyngeal tumors. 
The authors identified 11 discordant samples 
(p16+/HPV-) and according to authors, the p16 
overexpression detected by IHC reflects an altered 
pRb function induced by E7 viral oncoprotein; and 
this altered function may be secondary to mutation of 
the Rb gene regardless of HPV persistent infection 
[45]. Another hypothesis for explain these results can 
be attributed to PCR's failure to detect the viral DNA, 
which can be supported by the non-recognition of L1 
sequence of the viral genome with complementary 
primers used in the PCR [45]. Kawakami et al. (2003) 
showed that 11% of samples were p16+/HPV- and the 
authors suggested that these result reflect a 
deregulation in the Rb signaling pathway unrelated to 
HPV, as noted, for example, in small-cell lung cancer 
and lymphomas [46]. 
The inverse correlation between p16-/HPV+ is 
also questioned by some authors seeking to uncover if 
there is a chance of HPV playing its carcinogenic role 
in the esophagus without inducing the 
overexpression of p16. Among suggested hypotheses, 
one of them states that esophageal carcinogenesis may 
involve a high rate of p16 methylation promoters, 
thus inhibiting its expression in the oncogenic HPV 
infection [35]. It has been shown that there is loss of 
p16 expression secondary to promoter methylation in 
72% of ESCC cases [47], as it has been shown for other 
tumor types [48]. The current study also found similar 
results, since 23 samples (13.3%) were p16-/HPV+. 
Kawakami et al. (2013) reported that 20% of 
esophageal tumors were p16-/HPV+, and that most 
of these tumors showed methylation of the p16 gene 
promoter [46]. Similar results in head and neck 
carcinomas also showed p16-/HPV+ cases, although 
in lower frequencies [49-51]. 
We concluded that in this particular series, the 
prevalence of HPV in ESCC and healthy esophagus in 
the Brazilian population was identical, which 
suggested that the HPV does not necessarily has a role 
in the development of esophageal cancer since there 
was no association between the status of HPV and the 
expression of p53 and p16. 
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